TTK Healthcare Limited has published its Annual Report for the financial year ended March 31, 2026, presenting a mixed financial performance marked by revenue growth across most business segments, offset by a significant decline in profitability from the Protective Devices Division (PDD). The company's 68th Annual General Meeting (AGM) is scheduled for July 24, 2026, to be held via Video Conferencing / Other Audio Visual Means (VC/OAVM).

Financial Performance Overview

Revenue from operations for FY 2025-26 amounted to Rs.857.28 crores, compared to Rs.801.49 crores in the previous year, reflecting a growth of around 7%. Total income, including other income of Rs.7,215.00 lakhs, stood at Rs.92,943.11 lakhs. Profit before exceptional items and tax was Rs.86.64 crores, against Rs.94.43 crores in the previous year. After accounting for exceptional items, Profit Before Tax stood at Rs.82.56 crores (Previous Year – Rs.108.33 crores).

The following table summarises the key financial results for FY 2025-26 versus FY 2024-25:

Exceptional items for FY 2025-26 comprised a provision of Rs.757.87 lakhs (net) arising from the notification of the New Wage Code (Gratuity: Rs.823.02 lakhs and Long-term Compensated Absences: Rs.284.85 lakhs, net of a prior provision of Rs.350 lakhs) and a GST refund of Rs.350.42 lakhs recognised as exceptional income.

Segmentwise Performance

The company operates across Consumer Products, Animal Welfare, Medical Devices, Protective Devices, Pleasure Products, and Foods segments. Key segment revenues for FY 2025-26 are presented below:

• Animal Welfare Division (AWD): Reported revenue of Rs.141.08 crores, reflecting growth of around 12%. Bovianim (Livestock) recovered with ~14% growth, Gallus (Poultry) grew ~12%, and Aquanim (Aquaculture) registered ~33% growth on a lower base. Companim (Pet Care) grew 5%.
• Consumer Products Division (CPD): Reported revenue of Rs.241.28 crores (excluding Skore), with a negative growth of around 1.50%. Skore Condoms recorded 6% value growth.
• Heart Valve Division: Revenue of Rs.29.81 crores, with growth of around 2%.
• Ortho Division: Revenue of Rs.77 crores, registering growth of 27%.
• Protective Devices Division (PDD): Revenue of Rs.216.50 crores (including Skore), reflecting growth of around 5%. However, the division reported a segment-level loss of Rs.(1,054.25) lakhs, primarily due to the cessation of USAID business and non-establishment of the Long-Term Agreement with UNFPA.
• Foods Division: Revenue of Rs.150.36 crores, with annual growth of 14%.

Balance Sheet Highlights

Key balance sheet metrics as at March 31, 2026 are summarised below:

The Paid-up Equity Share Capital as on March 31, 2026 stood at Rs.1,413.03 lakhs, unchanged from the previous year. The company has not issued any shares with differential voting rights, stock options, or sweat equity.

Key Financial Ratios

The following key financial ratios reflect the company's performance for FY 2025-26:

Adverse changes in Operating Profit Margin, Net Profit Margin, Return on Equity, and Return on Capital Employed were primarily attributable to lower profit from PDD due to loss of institutional/tender business from USAID and UNFPA, higher brand promotional expenses relating to CPD and Pleasure Products, and higher Exceptional Income (Net) in the previous year compared to the current year.

Dividend and Corporate Actions

The Board of Directors has recommended a final dividend of Rs.10 per equity share (100%) for the financial year ended March 31, 2026, consistent with the previous year's dividend of Rs.10.00 (100%) per equity share. The dividend payout is in accordance with the company's Dividend Distribution Policy. The Record Date for determining shareholder entitlement to dividend is fixed as July 17, 2026.

During FY 2025-26, the company transferred Rs.6,23,463.07 to the Investor Education and Protection Fund (IEPF) representing unclaimed dividends for the year ended March 31, 2018. Additionally, 4,244 Equity Shares of Rs.10 each were transferred to the Demat Account of the IEPF Authority on September 24, 2025 and September 29, 2025.

Foreign Exchange and R&D

The company's foreign exchange earnings (Exports FOB) for FY 2025-26 stood at Rs.52,26,40,193, compared to Rs.83,11,90,053 in FY 2024-25. Total foreign exchange outgo for FY 2025-26 amounted to Rs.36,02,45,298 (FY 2024-25: Rs.32,85,16,139). R&D expenditure for the year was Rs.20,44,612, representing 0.02% of sales, compared to Rs.16,38,071 (0.02% of sales) in the previous year.

CSR and Other Disclosures

The company's total CSR obligation for FY 2025-26 was Rs.164.31 lakhs (2% of average net profit of Rs.8,215.40 lakhs). Against this, Rs.165.00 lakhs was spent during the year, with no unspent amount. The Board met 6 (Six) times during FY 2025-26. The company earned the "Great Place to Work" certification for the third consecutive year with an NPS of 95%, and was ranked 52nd among India's Top 100 Great Mid-Size Workplaces. As on March 31, 2026, the employee strength stood at 1,478 (Previous Year – 1,508). Capital expenditure for the year amounted to Rs.3.90 crores, with estimated normal Capex of around Rs.20 crores planned for FY 2026-27.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE910C01018/317fcd086d094925.pdf

TTK Healthcare Limited has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 with the stock exchanges. The report outlines the company's adherence to the nine principles of the SEBI framework on sustainability reporting, detailing its environmental and social performance.

The company reported a total workforce of 3,633 individuals, comprising 1,259 employees and 2,374 workers. The gender diversity among employees stood at 8.34% female representation, while workers had a 40.61% female representation. TTK Healthcare achieved 100% coverage for health and safety training for both employees and workers during the year.

Operational and Environmental Metrics

TTK Healthcare's operations span 8 plants and 41 offices nationally, serving 28 states and 8 union territories in India, along with 28 international markets. Exports contributed 6.41% to the total turnover. The company's product portfolio includes male contraceptives, food products, animal welfare products, ayurvedic preparations, medical devices, home care products, and cosmetics.

On the environmental front, the company reported a total energy consumption of 1,48,950.69 Gigajoules, with an energy intensity of 173.75 GJ per crore of turnover. Water consumption stood at 79,068 kilolitres, with a water intensity of 92.23. The total waste generated was 1,057.11 metric tonnes, resulting in a waste intensity of 1.23 per crore of turnover. The company recycled 1,056.71 metric tonnes of waste.

Employee Welfare and Governance

The company spent 0.84% of its total revenue on employee well-being measures. All permanent employees and workers were covered by Provident Fund, while 100% of permanent employees and 73.72% of permanent workers were covered by Gratuity. The Board of Directors comprised 20% female representation, and Key Management Personnel had 33% female representation.

TTK Healthcare confirmed that it has not undertaken any independent assessment or assurance of the BRSR Core. The report also highlighted the company's material sustainability issues, including product stewardship, sustainability and innovation, and customer relationships, all identified as opportunities. The company has implemented an Occupational Health and Safety management system at all locations and maintains a vigil mechanism for grievance redressal.